Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal
BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist’s potential new cancer drug. Under the agreement, Kumquat will be responsible for initiating and completing a phase-Ia study into the drug, a KRAS G12D inhibitor, while Bayer will complete development …
Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal Read More »









